FindTrial
Sign In

Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes

BIOLOGICAL2 trials

Sponsors

City of Hope Medical Center

Conditions

Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8

Phase 1

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
Active, not recruitingNCT03873805
City of Hope Medical CenterCastration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVA Prostate Cancer AJCC v8 +2
Start: 2019-08-20End: 2026-04-13Updated: 2025-06-26
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
RecruitingNCT05805371
City of Hope Medical CenterCastration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Start: 2024-07-19End: 2028-11-11Target: 21Updated: 2025-11-19

Related Papers

Abstract 3746: Single-cell liquid biopsy profiling in mCRPC receiving PSCA-targeted CAR-T cell therapy
Cancer Research2026-04-03
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.
2024-06-1259 citations
A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology2024-06-013 citations
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2023-06-019 citations
360 Novel immunotherapy for prostate cancer combining CAR T cells and myeloid cell STAT3 inhibition
Regular and Young Investigator Award Abstracts2022-11-01
Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T cell therapy for metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2022-02-1619 citations
A phase I study to evaluate PSCA-targeting chimeric antigen receptor (CAR)-T cells for patients with PSCA+ metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2020-02-199 citations